Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2020 | 2 |
2021 | 1 |
2022 | 2 |
2023 | 1 |
2024 | 0 |
Search Results
6 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
Efficacy and safety of gefapixant, a P2X3 receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials.
Lancet. 2022 Mar 5;399(10328):909-923. doi: 10.1016/S0140-6736(21)02348-5.
Lancet. 2022.
PMID: 35248186
Clinical Trial.
Efficacy and Safety of Gefapixant for Refractory or Unexplained Chronic Cough over 52 Weeks.
Birring SS, Dicpinigaitis PV, Smith JA, Morice AH, McGarvey LP, Pavord ID, Nguyen AM, Schelfhout J, Li Q, Iskold B, Green SA, Philip G, Muccino DR, La Rosa C.
Birring SS, et al. Among authors: muccino dr.
Am J Respir Crit Care Med. 2023 Jun 1;207(11):1539-1542. doi: 10.1164/rccm.202211-2128LE.
Am J Respir Crit Care Med. 2023.
PMID: 36996347
Free PMC article.
No abstract available.
Item in Clipboard
Validation and Meaningful Change Thresholds for an Objective Cough Frequency Measurement in Chronic Cough.
Schelfhout J, Nguyen AM, Birring SS, Bacci ED, Vernon M, Muccino DR, La Rosa C, Smith JA.
Schelfhout J, et al. Among authors: muccino dr.
Lung. 2022 Dec;200(6):717-724. doi: 10.1007/s00408-022-00587-2. Epub 2022 Nov 8.
Lung. 2022.
PMID: 36348054
Free PMC article.
Clinical Trial.
Item in Clipboard
Characterization of Patients With Refractory or Unexplained Chronic Cough Participating in a Phase 2 Clinical Trial of the P2X3-Receptor Antagonist Gefapixant.
Morice AH, Birring SS, Smith JA, McGarvey LP, Schelfhout J, Martin Nguyen A, Xu ZJ, Wu WC, Muccino DR, Sher MR.
Morice AH, et al. Among authors: muccino dr.
Lung. 2021 Apr;199(2):121-129. doi: 10.1007/s00408-021-00437-7. Epub 2021 Apr 7.
Lung. 2021.
PMID: 33825965
Free PMC article.
Clinical Trial.
Item in Clipboard
Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial.
Smith JA, Kitt MM, Morice AH, Birring SS, McGarvey LP, Sher MR, Li YP, Wu WC, Xu ZJ, Muccino DR, Ford AP; Protocol 012 Investigators.
Smith JA, et al. Among authors: muccino dr.
Lancet Respir Med. 2020 Aug;8(8):775-785. doi: 10.1016/S2213-2600(19)30471-0. Epub 2020 Feb 25.
Lancet Respir Med. 2020.
PMID: 32109425
Clinical Trial.
Item in Clipboard
Design and rationale of two phase 3 randomised controlled trials (COUGH-1 and COUGH-2) of gefapixant, a P2X3 receptor antagonist, in refractory or unexplained chronic cough.
Muccino DR, Morice AH, Birring SS, Dicpinigaitis PV, Pavord ID, Assaid C, Kleijn HJ, Hussain A, La Rosa C, McGarvey L, Smith JA.
Muccino DR, et al.
ERJ Open Res. 2020 Nov 2;6(4):00284-2020. doi: 10.1183/23120541.00284-2020. eCollection 2020 Oct.
ERJ Open Res. 2020.
PMID: 33263037
Free PMC article.
Item in Clipboard
Cite
Cite